___

• 1. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985;313:837-41.
• 2. Hersh JH, Danhauer DE, Hand ME, Weisskopf B. Retinoic acid embryopathy: timing of exposure and effects on fetal development. JAMA 1985;254:909–10.
• 3. Webster WS, Johnston MC, Lammer EJ, Sulik KK. Isotretinoin embryopathy and the cranial neural crest: an in vivo and in vitro study. J Craniofac Genet Dev Biol 1986;6:211–22.
• 4. Nulman I, Berkovitch M, Klein J, et al. Steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: implications for fetal safety. J Clin Pharmacol 1998;38:926–30.
• 5. Lee SM, Kim HM, Lee JS, et al. A case of suspected isotretinoin-induced malformation in a baby of a mother who became pregnant one month after discontinuation of the drug. Yonsei Med J 2009;50:445–7.
• 6. Johnson BA, Nunley JR. Use of systemic agents in the treatment of acne vulgaris. Am Fam Physician 2000;62:1823-30.
• 7. Jones KL. Smith’s recognizable pattern of human malformation. 6th ed. Philadelphia: Elsevier Saunders, 2006: 660-1.
• 8. Ceviz N, Özkan B, Eren S, Ors R, Olguntürk R. A case of isotretinoin embryopathy with bilateral anotia and Taussig-Bing malformation. Turk J Pediatr 2000;42:239-41.